SCFS
BCLI

S.C. Financial Services’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

S.C. Financial Services’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$20.8K Buy
+846
New +$31.6K 0.03% 118
2022
Q3 		– Sell
-1,698
Closed -$70K – 111
2022
Q2 		$70K Buy
1,698
+679
+67% +$30.6K 0.11% 117
2022
Q1 		$51K Hold
1,019
– – 0.07% 121
2021
Q4 		$52K Buy
+1,019
New +$50.2K 0.06% 125

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

S.C. Financial Services's BCLI Position: Q4 2022 in Review

S.C. Financial Services opened a new position in BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2022: 846 shares worth $20.8K. The stake represents 0.03% of the portfolio and ranks #118 among its holdings. This is a return to the name: S.C. Financial Services previously reported a position in BCLI as recently as Q2 2022.

S.C. Financial Services first reported a position in BCLI in Q4 2021 and has held it in 4 quarters since. The position peaked at $70K in Q2 2022. 43 funds tracked by Wall St. Rank hold BCLI as of Q4 2022.

  • S.C. Financial Services held 846 shares of BRAINSTORM CELL THERAPUTC worth $20.8K as of Q4 2022.
  • BRAINSTORM CELL THERAPUTC was a new S.C. Financial Services position in Q4 2022.
  • BRAINSTORM CELL THERAPUTC made up 0.03% of S.C. Financial Services's portfolio in Q4 2022, its #118 holding.
  • S.C. Financial Services first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2021 and has held it in 4 quarters since.
  • S.C. Financial Services's BRAINSTORM CELL THERAPUTC position peaked at $70K in Q2 2022.
  • 43 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2022.

Based on S.C. Financial Services's 13F filing for Q4 2022, filed 20 Jan 2023.